Researchers found that colibactin-induced mutational signatures were enriched in early-onset colorectal cancer cases.

Responses to an interview study demonstrated that patient education on palliative care led to better understanding of its benefits and greater utilization of these services.

This is not the first trial to show a lack of benefit when adding immunotherapy to SBRT in patients with early-stage, inoperable NSCLC.

Adjuvant cemiplimab could be a new standard of care for patients with cutaneous squamous cell carcinoma at high risk of recurrence, according to Danny Rischin, MD.

Children with ALL who were overweight or obese at 2 or more time points had an increased risk of relapse and death.

In an average-risk colorectal cancer screening population, a blood-based circulating tumor DNA test is feasible.

References: Kishan AU, Sun Y, Tree AC, et al. Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortium ...

The cohorts had similar proportions of females (39% and 40%), non-White (6% vs 4%) and Hispanic (4% vs 1%) patients, those with newly-diagnosed disease (42% for both), and months post MM diagnosis ...

Among the included patients, 1359 (43.8%) had uncontrolled pain, and 1044 (33.6%) experienced high-impact pain. Patients with uncontrolled pain were nearly 10 times more likely to develop OUD ...

HealthDay News — Rates of colorectal cancer detection through colonoscopy screening are similar for adults aged 45 to 49 years and 50 to 54 years, according to a research letter published online ...

Combination treatment with zanubrutinib and venetoclax has elicited durable responses in patients with treatment-naïve chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and ...

The Food and Drug Administration (FDA) has approved a new tablet formulation of Brukinsa ® (zanubrutinib), which is expected to replace the current capsule formulation in October 2025. Brukinsa ...